A year's experience of L-DOPA in the treatment of Parkinson's disease.
D000328:Adult; D000367:Age Factors; D000368:Aged; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D007839:Functional Laterality; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000188:drug therapy; D009325:Nausea / Q000139:chemically induced; D010300:Parkinson Disease / Q000145:classification / Q000188:drug therapy*; D010301:Parkinson Disease, Postencephalitic / Q000188:drug therapy; D013035:Spasm / Q000188:drug therapy; D013997:Time Factors; D014202:Tremor / Q000188:drug therapy
D004295:Dihydroxyphenylalanine